Form 4: CytoDyn CFO Robert Hoffman Granted 1 Million Stock Options
SEC Form 4 Filing
CytoDyn's Chief Financial Officer, Robert E. Hoffman, was granted 1,000,000 non-qualified stock options on May 15, 2025, according to a Form 4 filing.
Summary
- Robert E. Hoffman, the Chief Financial Officer of CytoDyn Inc., was granted 1,000,000 non-qualified stock options on May 15, 2025.
- The options have an exercise price of $0.41.
- The grant was approved by the Company's Compensation Committee under the 2012 Equity Incentive Plan.
- 250,000 shares will vest on May 15, 2026, with the remaining shares vesting in equal monthly installments from May 2026 through April 2029.
- The options expire on May 15, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and can be seen as a positive sign of aligning management's interests with shareholders. However, it also represents potential future dilution.
Positives
- The granting of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment and performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The specific terms of the grant, such as the vesting schedule and exercise price, are tailored to the company's specific circumstances and goals.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options as part of their compensation packages.
- The vesting schedules and exercise prices vary depending on the company's size, stage of development, and overall compensation strategy.
Stakeholder Impact
- Shareholders may experience potential dilution if the options are exercised.
- Employees may view the grant as a positive sign of the company's commitment to its executives.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the stock option grant. |
| 05/15/2026 | Date when the first 250,000 shares begin to vest. |
| April 2029 | End of the monthly vesting period for the remaining shares. |
| 05/15/2035 | Expiration date of the stock options. |
| 05/22/2025 | Date of the Form 4 filing. |
Keywords
stock options, CytoDyn, Robert E. Hoffman, CFO, equity incentive plan, vesting, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.